Abstract
Since the first generation of MAO inhibitors was developed, more than fifty years ago, this family of drugs has been ups and downs over the last decades. Actually, interest in MAO inhibitors is reviving and the emergence of new advances in the rational design of molecules and new techniques to predict the in vivo behavior has encouraged the research for new drugs with therapeutic potential in this area. The classic MAOIs have been widely used as antidepressants during the two decades after its introduction in clinic. Based on observations made on MAO inhibition by these drugs, it has been postulated hypothesis that have contributed to a better understanding of the mechanism and management of depressive disorders. However, exaggerated concerns about food and drug interactions relegated these drugs from the pharmaceutical landscape. The correct interpretation and the contextualization of side effects and the recent research findings, in which MAO selective inhibitors appear as promising agents in the treatment of emerging and high prevalence diseases, are placing these drugs again into the scientific and pharmacological focus.
Keywords: Antidepressants, depression, iproniazid, MAOIs, MAO-A selective inhibitors, moclobemide
Current Topics in Medicinal Chemistry
Title:History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug
Volume: 12 Issue: 20
Author(s): Matilde Yanez, Juan Fernando Padin, Juan Alberto Arranz-Tagarro, Mercedes Camina and Reyes Laguna
Affiliation:
Keywords: Antidepressants, depression, iproniazid, MAOIs, MAO-A selective inhibitors, moclobemide
Abstract: Since the first generation of MAO inhibitors was developed, more than fifty years ago, this family of drugs has been ups and downs over the last decades. Actually, interest in MAO inhibitors is reviving and the emergence of new advances in the rational design of molecules and new techniques to predict the in vivo behavior has encouraged the research for new drugs with therapeutic potential in this area. The classic MAOIs have been widely used as antidepressants during the two decades after its introduction in clinic. Based on observations made on MAO inhibition by these drugs, it has been postulated hypothesis that have contributed to a better understanding of the mechanism and management of depressive disorders. However, exaggerated concerns about food and drug interactions relegated these drugs from the pharmaceutical landscape. The correct interpretation and the contextualization of side effects and the recent research findings, in which MAO selective inhibitors appear as promising agents in the treatment of emerging and high prevalence diseases, are placing these drugs again into the scientific and pharmacological focus.
Export Options
About this article
Cite this article as:
Yanez Matilde, Fernando Padin Juan, Alberto Arranz-Tagarro Juan, Camina Mercedes and Laguna Reyes, History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug, Current Topics in Medicinal Chemistry 2012; 12 (20) . https://dx.doi.org/10.2174/1568026611212200011
DOI https://dx.doi.org/10.2174/1568026611212200011 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotransmitter Regulation of Adult Neurogenesis: Putative Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets QSAR Studies on some Calcium Channel Blockers
Letters in Drug Design & Discovery Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Synthesis and Biological Evaluation of New 4-Thiazolidinone Derivatives as Carbonic Anhydrase Inhibitors
Letters in Organic Chemistry The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Editorial [Hot Topic: Monotherapy to Polytherapy: Antiepileptic Drug Conversions Through the Spectrum of Epilepsy Care (Guest Editor: Erik K. St. Louis)]
Current Neuropharmacology Rational Understanding of Nicotinic Receptors Drug Binding
Current Topics in Medicinal Chemistry Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Recent Patents on Biotechnology Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design